Startup · $2.5m raised
Every investor coverage indicates participated in a round Emyria raised.
| Investor | Rounds | Invested |
|---|---|---|
| Sixty Two Capital | Unnamed stage | - |
| Taylor Collison | Unnamed stage | - |
| Tenmile | Unnamed stage | - |
Companies Emyria acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Michael Winlo | Managing Director | Startup Daily |
Stories naming Emyria. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Therapeutic psychedelics biotech Emyria has banked $2.5 million via a share placement co-led by Sixty Two Capital and Taylor Collison, with follow-on from Andrew Forrest's Tenmile, funding MDMA- and psilocybin-assisted therapy and cannabinoid trials.
Biotech Aravax has received a US$20 million Series B commitment from Brandon Capital and Tenmile to advance its peanut allergy therapy PVX108 into Phase 2 trials.
Also Brandon Capital portfolio·Startup Daily·Startup News (WA)·Techboard·Startup Daily
Andrew Forrest's private investment company Tattarang is launching Tenmile, a Perth-based $250 million health-tech venture fund that has already backed Emyria and Carina Biotech and partnered with Rock Health.
Roundup of manufacturing briefs: Fable Foods raises seed funding for mushroom-based meat, Nufarm wins US FDA recognition, Alexium commercialises BioCool, Archer patents its quantum chip in Asia, and Cann Group ends its Emyria collaboration.